10 defensive stocks that can also provide you with growth and dividends over the long termMarket Watch • 08/10/22
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple MyelomaBusiness Wire • 08/10/22
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 HighlightsBusiness Wire • 08/03/22
Famed "Big Short" Investor Loves This Multibillion-Dollar Company -- Should You?The Motley Fool • 08/03/22
These eight health-care stocks can keep you invested in the market with less worryMarket Watch • 08/02/22
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell CarcinomaBusiness Wire • 07/29/22
Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/27/22
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022Investors Business Daily • 07/27/22